title: Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event.
abstract: BACKGROUND
  Oral ivermectin is an alternative therapy for human scabies infection due to its ease of administration and good safety profile. However, there is no definitive consensus on the optimal dosing regimen.
  
  
  OBJECTIVE
  To describe the treatment of human scabies with different dosages of oral ivermectin and the possible adverse events.
  
  
  METHODS
  23 patients with human scabies were treated with oral ivermectin: 10 patients received a single oral dose of 200μg/kg and 13 a dose of 400μg/kg. A second, or even a third dose, was administered in cases of treatment failure.
  
  
  RESULTS
  A complete clinical response was achieved by all of the patients. The first ten patients required at least two (80%) or three (20%) doses of ivermectin for complete resolution of the infection. The remaining cases resolved with a single 400μg/kg oral dose. Within the first 72h after the administration of oral ivermectin, new cutaneous lesions were observed in eleven patients (47.8%). Cutaneous biopsies showed signs of subacute eczema. The eruption was treated with topical corticosteroids and emollient therapy. There was no other new drug administration or a history of irritants. There was no history of atopic diathesis except for one patient.
  
  
  CONCLUSIONS
  Oral ivermectin is an effective therapy for the treatment of human scabies. A single 400μg/kg oral dose demonstrated high efficacy and good tolerance. However, the appearance of eczematous cutaneous lesions induced by oral ivermectin has not previously been reported in the literature. Dermatologists should be aware of this possible adverse event.
authors.affiliation: Department of Dermatology, Hospital Rey Juan Carlos, Spain. Electronic address: josefina.sanz@gmail.com.
authors.forename: J
authors.initials: J
authors.lastname: Sanz-Navarro
authors.affiliation: Department of Dermatology, Hospital Universitario La Princesa, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Feal
authors.affiliation: Department of Dermatology, Hospital Universitario La Princesa, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Dauden
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology* / Q000517:prevention & control; D004485:Eczema / Q000139:chemically induced* / Q000517:prevention & control; D004643:Emollients / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D012532:Scabies / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000977:Antiparasitic Agents; D004643:Emollients; D007559:Ivermectin
keywords: Adverse events; Eccema; Eczema; Efectos adversos; Ivermectin; Ivermectina; Sarna; Scabies